Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer (PARTNER)
Randomised, Phase II/III, 3 Stage Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-based Neoadjuvant Chemotherapy in Breast Cancer Patients With TNBC and/or gBRCA.
Sponsor: AstraZeneca
This PHASE2/PHASE3 trial investigates Breast Cancer and is currently actively recruiting participants. AstraZeneca leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Cambridge University Hospitals NHS Foundation Trust
- Cancer Research UK
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ayr, United Kingdom , Basingstoke, United Kingdom , Bedford, United Kingdom , Bournemouth, United Kingdom , Bristol, United Kingdom , Burton-on-Trent, United Kingdom , Bury St Edmunds, United Kingdom , Cambridge, United Kingdom , Cardiff, United Kingdom , Colchester, United Kingdom and 19 more locations